Omega’s shares rose 3.5% after earnings, with investors likely responding to the highly accretive PACS transition and the company’s deployment of more than $1 billion in the second half to date. Sequential AFFO and FAD were effectively flat, tempering the positive operating and transaction updates.
Shares declined 1.4% following Q2 results as investors reacted cautiously to flat sequential AFFO and ongoing asset sales weighing on near-term earnings, despite management’s optimism on longer-term earnings accretion from capital redeployment.
Omega Healthcare Investors shares drifted 0.9% lower post-earnings as results and outlook were largely in line with expectations. Though management highlighted a rising AFFO guidance midpoint and strong FAD growth, no upside surprise or disappointment was evident.